Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Ischemic stroke is the leading cause of long-term disability in the United States.
Endovascular intervention with mechanical thrombectomy has become the standard of care for
acute large vessel occlusion (LVO) stroke since multiple clinical trials demonstrated
improved long-term clinical outcomes with treatment. However, despite high rates of
successful vessel recanalization and thus reperfusion of ischemic brain tissue in current
practice, many patients continue to suffer debilitating strokes and poor long-term functional
outcome. Pharmacologic neuroprotection could potentially present a means of addressing this
mismatch in radiologic vs. clinical outcomes by protecting and salvaging damaged brain
tissue. Intra-arterial delivery of a cocktail of neuroprotective therapy at the time of
endovascular reperfusion would provide immediate, targeted therapy directly to the damaged
brain territory. Hypothermia, minocycline and magnesium can target multiple facets of the
complex ischemic injury cascade, and have each demonstrated neuroprotection in multiple
preclinical models. This is a phase I trial that aims to demonstrate safety and feasibility
of administering cold saline, minocycline, and magnesium sulfate intra-arterially immediately
after thrombectomy in stroke interventions.